when were glp 1 agonists approved Evolution of GLP‐1 Receptor for Diabetes Treatment History of glucagon-like peptide-1 receptor

Does the use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonists have clinically significant effects on residual gastric volume (RGV) in the periprocedural period

and in July 2024, the FDA approved Kisunla (donanemab) for early symptomatic Alzheimers, based on evidence of reduced clinical decline and a limitedduration regimen tied to amyloid plaque removal

Here, we aimed to provide an overview of retatrutide's safety and effectiveness in treating obesity.

Starting Jan.1, 2026, Pennsylvania will limit GLP1 weightloss drugs under Medicaid threatening access for thousands of lowincome patients.

Over the past year, Ive seen a growing number of patients achieving remarkable weight-loss success with GLP-1 medications

As with other complex diseases, the next era likely involves precision, combination therapypairing antiamyloid agents with treatments aimed at metabolic, inflammatory, vascular, and synaptic pathways